S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.58 HKD 3.77% Market Closed
Market Cap: 10.6B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

Gross Margin
SSY Group Ltd

54.4%
Current
57%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
54.4%
=
Gross Profit
3.5B
/
Revenue
6.5B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
HK
SSY Group Ltd
HKEX:2005
10.6B HKD
54%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
749.1B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
348B USD
69%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
77%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
82%
CH
Novartis AG
SIX:NOVN
171.5B CHF
75%
US
Pfizer Inc
NYSE:PFE
150.1B USD
71%
Country HK
Market Cap 10.6B HKD
Gross Margin
54%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.1B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 348B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 150.1B USD
Gross Margin
71%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
10.6B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
5.43 HKD
Undervaluation 34%
Intrinsic Value
Price
S

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
54.4%
=
Gross Profit
3.5B
/
Revenue
6.5B
What is the Gross Margin of SSY Group Ltd?

Based on SSY Group Ltd's most recent financial statements, the company has Gross Margin of 54.4%.